Table 3.

Ongoing Trials for Preoperative Neoadjuvant Systemic Therapies.

Experimental Arm	Comparison Arm	Patient Population	Phase	Primary Outcome(s)	Registration	Reference
Nivolumab plus ipilimumab	None	40 patients with potential for curative surgical resection	II	Percentage of patients with tumor shrinkage > 10%	NCT03510871	[21]
Camrelizumab plus apatinib mesylate plus oxaliplatin	None	15 participants with locally advanced, potentially resectable disease	II	Major pathological response (>90% tumor necrosis)	NCT04850040	[22]
Sorafenib plus capecitabine plus oxaliplatin	None	15 participants with HCC confined to a single lobe and not suitable for surgery or locoregional therapies	II	Proportion of patients with resectable disease	NCT03578874	[23]
Sintilimab plus transarterial chemoembolization	None	61 patients with BCLC stage A (not transplantable) or stage B (ineligible for resection)	II	Duration from treatment initiation to disease progression in patients who cannot undergo surgery, or to the date of relapse after surgery, or death	NCT04174781	[24]
Tislelizumab plus intensity modulated radiation therapy	None	30 patients with resectable disease and portal vein tumor thrombus	II	Relapse-free survival	NCT04850157	[24]
Sorafenib plus laser ablation	Laser ablation	40 patients with unresectable HCC containing one nodule larger than 4 cm in diameter	II	Complete tumor ablation rate, time-to-recurrence (in complete response group), time-to-progression (in partial response group)	NCT01507064	[25]
Atezolizumab plus bevacizumab plus stereotactic beam radiation therapy	None	20 patients with resectable disease	I	Proportion of patients with grade 3 or 4 treatment-related adverse events	NCT04857684	[26]
Anlotinib hydrochloride plus TQB2450 (antibody against PD-L1)	None	20 patients with resectable disease	Ib	Pathologic complete response rate, overall response rate	NCT04888546	[27]
Atezolizumab plus bevacizumab	None	30 participants with resectable HCC	II	Pathologic complete response rate Safety/tolerability	NCT04721132	[28]

Downstaging Neoadjuvant Therapies Prior to Transplant.